NCT03785574Recruiting
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule，A Prospective Multicentre Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). Lung nodule \<1.0cm will directly treated as group C
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 21 Dec 2018
- Start date
- 24 Dec 2018
- Primary completion date
- 1 Sept 2030
- Lead sponsor
- Women's Hospital School Of Medicine Zhejiang University
- NCT number
- NCT03785574
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 24 Dec 2018 to the primary completion date, 1 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patients with a previous history of lung nodules.
- The patients have undergone prophylactic hysterectomy or chemotherapy.
Other illness
- The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc.
- Patients have immunosuppressive diseases or take immunosuppressants.
Other
- Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment.
- Patients are participating in other clinical trials at same time.
- Patients were unable or unwilling to provide written informed consent.
Who the study is looking for
- Eligible patients have to meet all of the following criteria:
- Pathologically confirmed HM.
- The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage).
- The hCG level does not meet FIGO diagnostic criteria (2018) of GTN.
- The patients are willing to compliant with the study protocol and be followed up at regular intervals.
- The patients agree to sign an informed consent form.
Age in the registry: - to 60 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weiguo Lv Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.